Adam S. Grossman - 15 Aug 2023 Form 4 Insider Report for ADMA BIOLOGICS, INC. (ADMA)

Role
President and CEO, Director
Signature
/s/ Adam S. Grossman, by Brian Lenz as Attorney-in-fact
Issuer symbol
ADMA
Transactions as of
15 Aug 2023
Net transactions value
-$9,648,812
Form type
4
Filing time
17 Aug 2023, 21:30:51 UTC
Previous filing
05 Jul 2023
Next filing
18 Aug 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ADMA Common Stock Options Exercise $354,875 +212,500 +8.4% $1.67 2,735,585 15 Aug 2023 Direct
transaction ADMA Common Stock Options Exercise $651,258 +277,131 +10% $2.35 3,012,716 15 Aug 2023 Direct
transaction ADMA Common Stock Options Exercise $809,216 +277,604 +9.2% $2.92 3,290,320 15 Aug 2023 Direct
transaction ADMA Common Stock Options Exercise $1,288,000 +400,000 +12% $3.22 3,690,320 15 Aug 2023 Direct
transaction ADMA Common Stock Options Exercise $1,298,500 +350,000 +9.5% $3.71 4,040,320 15 Aug 2023 Direct
transaction ADMA Common Stock Options Exercise $2,134,600 +583,224 +14% $3.66 4,623,544 15 Aug 2023 Direct
transaction ADMA Common Stock Sale $2,318,959 -510,469 -11% $4.54 4,113,075 15 Aug 2023 Direct F1
transaction ADMA Common Stock Tax liability $7,329,840 -1,589,987 -39% $4.61 2,523,088 15 Aug 2023 Direct
transaction ADMA Common Stock Sale $13.16 -3 -0% $4.38 2,523,085 16 Aug 2023 Direct F2, F3, F4
holding ADMA Common Stock 1,143,426 15 Aug 2023 See Footnote F5
holding ADMA Common Stock 580,957 15 Aug 2023 See Footnote F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ADMA Common Stock Options Exercise $354,875 -212,500 -35% $1.67 387,500 15 Aug 2023 Common Stock 212,500 $1.67 Direct F7
transaction ADMA Common Stock Options Exercise $651,258 -277,131 -60% $2.35 181,569 15 Aug 2023 Common Stock 277,131 $2.35 Direct F8
transaction ADMA Common Stock Options Exercise $809,216 -277,604 -85% $2.92 47,396 15 Aug 2023 Common Stock 277,604 $2.92 Direct F9
transaction ADMA Common Stock Options Exercise $1,288,000 -400,000 -100% $3.22 0 15 Aug 2023 Common Stock 400,000 $3.22 Direct F10
transaction ADMA Common Stock Options Exercise $1,298,500 -350,000 -100% $3.71 0 15 Aug 2023 Common Stock 350,000 $3.71 Direct F11
transaction ADMA Common Stock Options Exercise $2,134,600 -583,224 -100% $3.66 0 15 Aug 2023 Common Stock 583,224 $3.66 Direct F12
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects the weighted average price of sales on August 15, 2023. The shares were sold in multiple transactions at prices ranging from $4.495 to $4.63, inclusive.
F2 Includes, as of the transaction date, (i) 573,695 RSUs granted on March 6, 2023 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 225,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 340,313 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the "Time-Based RSUs") which will vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date;
F3 (continued from footnote 2) (iv) 104,341 unvested RSUs granted on February 25, 2021, of which 91,575 unvested RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 12,766 unvested RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting;
F4 (continued from footnote 3) (v) 25,000 unvested RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (vi) 1,254,736 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.
F5 These shares are owned by Areth, LLC ("Areth"). The reporting person is a control person of Areth.
F6 These shares are owned by Hariden, LLC ("Hariden"). The reporting person is the managing member of Hariden.
F7 The options vest over four years with 25% of the shares of common stock underlying the options vesting on the one year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on March 7, 2026.
F8 The options vest over four years with 25% of the shares of Common Stock underlying the options vesting on the one year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 25, 2025.
F9 The options vest over four years with 25% of the shares of Common Stock underlying the options vesting on the one year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 28, 2024.
F10 The option vests over a four-year period with 25% of the shares of common stock underlying the option vesting on the one year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter beginning on February 23, 2020, becoming fully vested on January 23, 2023
F11 The option vests over a four year period with 25% of the shares of common stock underlying the option vesting on the one year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter beginning on March 9, 2019, becoming fully vested on February 9, 2022.
F12 The option vests over a four year period with 25% of the shares of common stock underlying the option vesting on the one year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter beginning on July 6, 2018, becoming fully vested on June 6, 2021.